Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy

Affiliations

• ¹ CRIMM, Centre of Research and Innovation in Myeloproliferative Neoplasms, University of Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Italy. Electronic address: alessandro.atanasio@unifi.it.
• ² Department of Experimental and Clinical Medicine, University of Florence, Italy.
• ³ CRIMM, Centre of Research and Innovation in Myeloproliferative Neoplasms, University of Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Italy.
• ⁴ Department of Experimental and Clinical Medicine, University of Florence, Italy; Infectious and Tropical Diseases Unit, Careggi University Hospital, Italy.
• ⁵ Microbiology and Virology Unit, Careggi University Hospital, Italy.
• ⁶ CRIMM, Centre of Research and Innovation in Myeloproliferative Neoplasms, University of Florence, Italy.
• ⁷ Department of Experimental and Clinical Medicine, University of Florence, Italy; Microbiology and Virology Unit, Careggi University Hospital, Italy.
• ⁸ Department of Experimental and Clinical Medicine, University of Florence, Italy; Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University Hospital, Italy.